Jazz Pharmaceuticals PLC (JAZZ) stock is soaring 5.01% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report and raised guidance for 2025. The biopharmaceutical company specializing in sleep and hematology/oncology therapies has outperformed market expectations, leading to increased investor confidence.

Jazz Pharmaceuticals reported a non-GAAP earnings per share (EPS) of $8.13 for Q3, significantly surpassing the FactSet analyst consensus of $5.80. This represents a substantial increase from $6.54 in the same quarter last year. The company's revenue also showed strong growth, reaching $1.13 billion, up from $1.05 billion a year earlier and slightly above the $1.11 billion anticipated by analysts.

In a move that has further bolstered investor sentiment, Jazz Pharmaceuticals raised its 2025 adjusted EPS guidance to between $7.65 and $8.45 per share, up from the previous range of $4.80 to $5.60. The company also narrowed its annual total revenue guidance to between $4.18 billion and $4.28 billion. These positive developments have prompted several analysts to revise their price targets upward, with Morgan Stanley raising its target to $185 from $183 and RBC increasing its target to $155 from $151, both maintaining positive ratings on the stock. The average price target among analysts now stands at $188.56, indicating potential further upside for Jazz Pharmaceuticals' shares.